Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

PURPOSE: Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms of temozolomide resistance, or both. The goal of this randomized phase II study was to evaluate two differe...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Clarke, Jennifer L., Iwamoto, Fabio M., Sul, Joohee, Panageas, Katherine, Lassman, Andrew B., DeAngelis, Lisa M., Hormigo, Adília, Nolan, Craig P., Gavrilovic, Igor, Karimi, Sasan, Abrey, Lauren E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2009
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2727290/
https://ncbi.nlm.nih.gov/pubmed/19506159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.7944
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak